Hanyu Wang1, Tingting Zhao1, Fang Xu1, Yan Li1, Mingyuan Wu2, Delin Zhu1, Xiuli Cong3, Yongjun Liu4. 1. Alliancells Institute of Stem Cells and Translational Regenerative Medicine, Tianjin, China. 2. Alliancells Institute of Stem Cells and Translational Regenerative Medicine, Tianjin, China; Beijing Alliancells-PuRui Bioscience Co, Ltd, Beijing, China; University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. 3. Alliancells Institute of Stem Cells and Translational Regenerative Medicine, Tianjin, China; University of Florida, Department of Medicine, Gainesville, Florida, USA. 4. Alliancells Institute of Stem Cells and Translational Regenerative Medicine, Tianjin, China. Electronic address: andyliuliu2001@aliyun.com.
Abstract
BACKGROUND AIMS: The protocols for differentiation of hepatocyte-like cells (HLCs) from mesenchymal stromal cells (MSCs) have been well established. Previous data have shown that MSCs and their derived HLCs were able to engraft injured liver and alleviate injuries induced by carbon tetrachloride. The goal of the current study was to determine the differences of MSCs and their derived HLCs in terms of therapeutic functions in liver diseases. METHODS: After hepatic differentiation of umbilical cord-derived MSCs in vitro, we detected both MSC and HLC expressions of adhesion molecules and chemokine receptor CXCR4 by flow cytometry; immunosuppressive potential and hepatocyte growth factor expression were determined by means of enzyme-linked immunosorbent assay. We compared the therapeutic effect for fulminant hepatic failure in a mouse model. RESULTS: MSC-derived-HLCs expressed lower levels of hepatocyte growth factor, accompanied by impaired immunosuppression in comparison with MSCs. Furthermore, undifferentiated MSCs showed rescuing potentials superior to those in HLCs for the treatment of fulminant hepatic failure. CONCLUSIONS: After differentiation, HLCs lost several major properties in comparison with undifferentiated MSCs, which are beneficial for their application in liver diseases. Undifferentiated MSCs may be more appropriate than are HLCs for the treatment of liver diseases.
BACKGROUND AIMS: The protocols for differentiation of hepatocyte-like cells (HLCs) from mesenchymal stromal cells (MSCs) have been well established. Previous data have shown that MSCs and their derived HLCs were able to engraft injured liver and alleviate injuries induced by carbon tetrachloride. The goal of the current study was to determine the differences of MSCs and their derived HLCs in terms of therapeutic functions in liver diseases. METHODS: After hepatic differentiation of umbilical cord-derived MSCs in vitro, we detected both MSC and HLC expressions of adhesion molecules and chemokine receptor CXCR4 by flow cytometry; immunosuppressive potential and hepatocyte growth factor expression were determined by means of enzyme-linked immunosorbent assay. We compared the therapeutic effect for fulminant hepatic failure in a mouse model. RESULTS: MSC-derived-HLCs expressed lower levels of hepatocyte growth factor, accompanied by impaired immunosuppression in comparison with MSCs. Furthermore, undifferentiated MSCs showed rescuing potentials superior to those in HLCs for the treatment of fulminant hepatic failure. CONCLUSIONS: After differentiation, HLCs lost several major properties in comparison with undifferentiated MSCs, which are beneficial for their application in liver diseases. Undifferentiated MSCs may be more appropriate than are HLCs for the treatment of liver diseases.
Authors: Nate Watson; Ryan Divers; Roshan Kedar; Ankur Mehindru; Anuj Mehindru; Mia C Borlongan; Cesar V Borlongan Journal: Cytotherapy Date: 2014-10-18 Impact factor: 5.414
Authors: Oliver Kemper; Monika Herten; Johannes Fischer; Marcel Haversath; Sascha Beck; Tim Classen; Sebastian Warwas; Tjark Tassemeier; Stefan Landgraeber; Sabine Lensing-Höhn; Rüdiger Krauspe; Marcus Jäger Journal: Med Sci Monit Date: 2014-11-10